EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The pleiotropic effects of sotatercept

Giovanna Manzi, Enrico Maggio, Tommaso Recchioni, Francesca Ileana Adamo, Annalisa Caputo, Alexandra Mihai, Silvia Papa, Giorgia Serino, Gianmarco Scoccia, Roberto Badagliacca, Carmine Dario Vizza

Vascular Pharmacology · 2026

DOI: 10.1016/j.vph.2025.107577 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2026. Verfasst von Giovanna Manzi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Pulmonary Arterial Hypertension, Pulmonary Artery, Antihypertensive Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent randomized clinical trials (RCTs) have demonstrated the efficacy of sotatercept in the treatment of pulmonary arterial hypertension (PAH), leading to its approval by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This novel first-in-class fusion protein acts as a ligand trap for select members of the transforming growth factor-beta (TGF-β) superfamily, thereby exerting a broad spectrum of biological effects. These include vascular remodeling (via Activin A and B inhibition), enhancement of angiogenesis (through modulation of BMP-9), stimulation of erythropoiesis (by targeting GDF-11), and, to a lesser extent, modulation of skeletal muscle homeostasis (through GDF-8/myostatin inhibition). This review focuses on the pleiotropic effects of sotatercept, with the aim of encouraging the reader to delve deeper into the drug's multifaceted mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsPulmonary Arterial HypertensionPulmonary ArteryAntihypertensive AgentsHumansAnimalsSignal TransductionVascular RemodelingTransforming Growth Factor betaErythropoiesisMuscle, SkeletalNeovascularization, Physiologic

Stichwörter der Autor:innen

Pleiotropic effectsPulmonary arterial hypertensionSotatercept

Substanzen

Recombinant Fusion ProteinsTransforming Growth Factor betaAntihypertensive Agentssotatercept

Autor:innen und Institutionen

  • Department of Medical and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
  • Department of Medical and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161 Rome, Italy. Electronic address: roberto.badagliacca@uniroma1.it.

Zitieren

APA

Manzi, G., Maggio, E., Recchioni, T., Adamo, F. I., Caputo, A., Mihai, A., Papa, S., Serino, G., Scoccia, G., Badagliacca, R., & Vizza, C. D. (2026). The pleiotropic effects of sotatercept. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2025.107577

Vancouver

Manzi G, Maggio E, Recchioni T, Adamo FI, Caputo A, Mihai A, et al. The pleiotropic effects of sotatercept. Vascular Pharmacology. 2026. doi:10.1016/j.vph.2025.107577

BibTeX
@article{Manzi2026,
  author = {Manzi, Giovanna and Maggio, Enrico and Recchioni, Tommaso and Adamo, Francesca Ileana and Caputo, Annalisa and Mihai, Alexandra and Papa, Silvia and Serino, Giorgia and Scoccia, Gianmarco and Badagliacca, Roberto and Vizza, Carmine Dario},
  title = {The pleiotropic effects of sotatercept},
  journal = {Vascular Pharmacology},
  year = {2026},
  doi = {10.1016/j.vph.2025.107577}
}
Kostenlos starten →